{
    "clinical_study": {
        "@rank": "131220", 
        "arm_group": [
            {
                "arm_group_label": "Resveratrol", 
                "arm_group_type": "Active Comparator", 
                "description": "Active Comparator: Resveratrol\n1 Resveratrol capsules for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one capsule per day"
            }
        ], 
        "brief_summary": {
            "textblock": "To study the effects of Resveratrol supplement on lipid profile, liver enzymes, inflammatory\n      factors and hepatic fibrosis in patients with Nonalcoholic Fatty Liver (NAfLD), 50 patients\n      who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be randomly\n      allocated to receive 1 Resveratrol capsules or placebos for 12 weeks; both groups will be\n      advised to adherence our diet and exercise program too. At the first and the end of the\n      intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis\n      will be assessed and compared between groups."
        }, 
        "brief_title": "The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Non Alcoholic Fatty Liver", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 and older;\n\n          -  Evidence of nonalcoholic steatohepatitis with steatosis grade higher or equal to 1 in\n             ultrasonography;\n\n          -  No history of Alcohol consumption or consuming less than 10 grams alcohol per day in\n             women and less than 20 grams per day in men;\n\n          -  Absence of other liver disorders, malignancies, cardiovascular, respiratory, and\n             kidney disorders;\n\n          -  Absence of pregnancy or lactation;\n\n          -  Absence of taking any medications in the past three months;\n\n          -  Absence of weight loss in the recent three months;\n\n          -  Absence of endocrine and metabolism disorders.\n\n        Exclusion Criteria:\n\n          -  Weight loss more than 10% of baseline body weight during the intervention period.\n\n          -  Pregnancy;\n\n          -  Disliking to continue the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030977", 
            "org_study_id": "046468"
        }, 
        "intervention": [
            {
                "arm_group_label": "Resveratrol", 
                "intervention_name": "Resveratrol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Dietary Supplement: Resveratrol", 
                    "1 Resveratrol capsule per day for 12 weeks"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "number_of_arms": "2", 
        "official_title": "The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "IRAN: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Alaninaminotransferase(ALT)", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030977"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Nutrition and Food Technology Institute", 
            "investigator_full_name": "Dr Azita Hekmatdoost", 
            "investigator_title": "PI", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "National Nutrition and Food Technology Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr Azita Hekmatdoost", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}